Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N. Kyi C, et al. Among authors: sabado r. Clin Cancer Res. 2018 Oct 15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27. Clin Cancer Res. 2018. PMID: 29950349 Free PMC article.
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Pavlick A, et al. Among authors: sabado rl. Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7. Cancer Immunol Res. 2020. PMID: 31699709 Free PMC article. Clinical Trial.
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Saxena M, Sabado RL, La Mar M, Mohri H, Salazar AM, Dong H, Correa Da Rosa J, Markowitz M, Bhardwaj N, Miller E. Saxena M, et al. Among authors: sabado rl. Front Immunol. 2019 Apr 9;10:725. doi: 10.3389/fimmu.2019.00725. eCollection 2019. Front Immunol. 2019. PMID: 31024557 Free PMC article. Clinical Trial.
Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
Miller E, Spadaccia M, Sabado R, Chertova E, Bess J, Trubey CM, Holman RM, Salazar A, Lifson J, Bhardwaj N. Miller E, et al. Among authors: sabado r. Vaccine. 2015 Jan 3;33(2):388-95. doi: 10.1016/j.vaccine.2014.10.054. Epub 2014 Nov 15. Vaccine. 2015. PMID: 25444812 Free PMC article.
Dendritic cell-based immunotherapy.
Sabado RL, Balan S, Bhardwaj N. Sabado RL, et al. Cell Res. 2017 Jan;27(1):74-95. doi: 10.1038/cr.2016.157. Epub 2016 Dec 27. Cell Res. 2017. PMID: 28025976 Free PMC article. Review.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Sabado RL, et al. Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29. Cancer Immunol Res. 2015. PMID: 25633712 Free PMC article. Clinical Trial.
Dendritic Cell Vaccines.
Sabado RL, Meseck M, Bhardwaj N. Sabado RL, et al. Methods Mol Biol. 2016;1403:763-77. doi: 10.1007/978-1-4939-3387-7_44. Methods Mol Biol. 2016. PMID: 27076166
Dendritic cell immunotherapy.
Sabado RL, Bhardwaj N. Sabado RL, et al. Ann N Y Acad Sci. 2013 May;1284:31-45. doi: 10.1111/nyas.12125. Ann N Y Acad Sci. 2013. PMID: 23651191
22 results